AR106899A1 - COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO - Google Patents

COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO

Info

Publication number
AR106899A1
AR106899A1 ARP160103688A ARP160103688A AR106899A1 AR 106899 A1 AR106899 A1 AR 106899A1 AR P160103688 A ARP160103688 A AR P160103688A AR P160103688 A ARP160103688 A AR P160103688A AR 106899 A1 AR106899 A1 AR 106899A1
Authority
AR
Argentina
Prior art keywords
group
integer
alkyl
range
case
Prior art date
Application number
ARP160103688A
Other languages
English (en)
Inventor
Linney Ian
Rizzi Andrea
Rancati Fabio
Carzaniga Laura
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR106899A1 publication Critical patent/AR106899A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula general (1) donde Y es un grupo divalente de fórmula (2) donde A se selecciona entre el grupo que consiste en C₁₋₆ alquileno; B se encuentra ausente o se selecciona entre el grupo que consiste en C₃₋₈ cicloalquileno, C₃₋₈ heterocicloalquileno, arileno o heteroarileno opcionalmente sustituido con uno o más grupos seleccionados entre halógenos, -CN, C₁₋₆ alquilo, C₁₋₆ alcoxi y aril-C₁₋₆ alquilo; C se encuentra ausente o se selecciona entre el grupo que consiste en -O-, -C(O)-, -OC(O)-, -(O)CO-, -S-, -S(O)-, -S(O)₂- y -N(R⁵)-; n’ n’’ son en cada caso en forma independiente 0 o un entero entre 1 y 3; E se encuentra ausente o se selecciona entre -O-, -NR⁵-, -NR⁵-C(O)-, -C(O)-NR⁵-, -OC(O)- y -S-; W¹ se selecciona entre un grupo arileno divalente y un grupo heteroarileno divalente; R¹ y R² cuando están presentes se seleccionan en cada caso en forma independiente entre halógeno, C₁₋₆ alquilo y C₁₋₆ alcoxi; donde n y m son en cada caso en forma independiente 0 o un entero en el rango entre 1 y 3; L¹ es un grupo seleccionado entre: -(CH₂)ₜ-NR⁵-, -(CH₂)ₜ-C(O)-NR⁵-, -C(O)-NR⁵-(CH₂)ₜ-C(O)-NR⁵-; donde t es un entero en el rango entre 0 y 4; L² es -(CH₂)q- y L³ es -(CH₂)₂₋q-; donde q es un entero en el rango entre 0 y 2; s es un entero en el rango entre 0 y 3, R³ es un grupo que contiene nitrógeno que se selecciona entre los restos J1, J2, J3 y J4 del grupo de fórmulas (3); R⁴ es un grupo de fórmula (4) donde p es 0 o un entero entre 1 y 4; y W se selecciona entre el grupo que consiste en H, C₁₋₆ alquilo, C₃₋₈ cicloalquilo, arilo y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH; R⁵ se selecciona en cada caso en forma independiente entre el grupo que consiste en H, C₁₋₆ alquilo lineal o ramificado, C₃₋₈ cicloalquilo, C₃₋₈ heterocicloalquilo, arilo, heteroarilo; y solvatos o sales farmacéuticamente aceptables del mismo.
ARP160103688A 2015-12-03 2016-12-01 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO AR106899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197730 2015-12-03

Publications (1)

Publication Number Publication Date
AR106899A1 true AR106899A1 (es) 2018-02-28

Family

ID=54780197

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103688A AR106899A1 (es) 2015-12-03 2016-12-01 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO

Country Status (4)

Country Link
US (1) US9932338B2 (es)
EP (1) EP3383867B1 (es)
AR (1) AR106899A1 (es)
WO (1) WO2017093208A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018346709A1 (en) 2017-10-05 2020-04-16 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
US8138345B2 (en) 2009-04-23 2012-03-20 Theravance, Inc. Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
SI2718280T1 (sl) 2011-06-10 2015-12-31 Chiesi Farmaceutici S.P.A. Spojine, ki imajo aktivnost antagonista muskarinskega receptorja in beta2-adrenergičnega receptorja
RU2661877C2 (ru) 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
HUE051394T2 (hu) 2012-12-06 2021-03-01 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista aktivitással rendelkezõ vegyületek
AR104828A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO

Also Published As

Publication number Publication date
EP3383867B1 (en) 2021-04-14
US9932338B2 (en) 2018-04-03
WO2017093208A1 (en) 2017-06-08
US20170158694A1 (en) 2017-06-08
EP3383867A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
AR093832A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR121419A1 (es) Piridazinonas como inhibidoras de parp7
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR111419A1 (es) Compuestos fusionados de indazol piridona como antivirales
AR117617A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR089333A1 (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR103666A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
AR088023A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR093825A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR086896A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
PE20160992A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
AR106899A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
AR100327A1 (es) Inhibidores de quinasa relacionados con tropomiosina
AR108864A1 (es) Agentes antibacterianos
AR114926A1 (es) Derivados de azaindol como inhibidores de rho-quinasa
AR105929A1 (es) Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas
AR101255A1 (es) Derivados de isoindolinona
AR109950A1 (es) INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Legal Events

Date Code Title Description
FB Suspension of granting procedure